Levodopa/Carbidopa/Entacapone Stada

Levodopa, carbidopa, and entacapone, the active ingredients in Levodopa/Carbidopa/Entacapone Stada, are an antiparkinson agent presented as an oral tablet for oral use. The combination is employed to manage Parkinson's disease symptoms in adult patients. Levodopa is a dopamine precursor, carbidopa inhibits peripheral metabolism, and entacapone prolongs levodopa availability, together providing more consistent motor control.

GNH USA supplies Levodopa/Carbidopa/Entacapone Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Levodopa/Carbidopa/Entacapone is used in the management of Parkinson’s disease, targeting motor fluctuations and overall symptom control.

- Parkinson’s disease (early to advanced): improves motor function and reduces “off” periods. - Fluctuating Parkinson’s disease: provides smoother dopamine levels to lessen motor fluctuations. - Parkinson’s disease with wearing‑off: extends levodopa effect, decreasing dosing frequency.

Levodopa/Carbidopa/Entacapone may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Dizziness or light‑headedness - Orthostatic hypotension - Insomnia or vivid dreams - Dyskinesia (involuntary movements) - Constipation

Serious or Rare Side Effects: - Severe hypotension or syncope - Neuroleptic malignant‑like syndrome - Hallucinations or severe psychosis - Major depression or suicidal ideation - Cardiac arrhythmias - Anaphylaxis or severe allergic reactions - Significant liver enzyme elevations

Before initiating therapy, clinicians should consider individual patient factors and monitor for specific safety concerns.

- Dose adjustments: tailor dosing based on clinical response and tolerability. - Renal impairment: use with caution; monitor renal function. - Hepatic impairment: consider dose reduction; monitor liver enzymes. - Cardiovascular disease: monitor blood pressure and heart rate. - Pregnancy and lactation: safety not established; avoid unless essential. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Levodopa/Carbidopa/Entacapone can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Selective MAO‑B inhibitors (e.g., selegiline) combined with entacapone: may increase levodopa levels excessively. - Anticholinergics: may mask Parkinsonian symptoms. - Antipsychotics (dopamine antagonists): reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive hypotensive effect. - SSRIs/SNRIs: may increase risk of serotonin syndrome. - Iron supplements: decrease levodopa absorption; separate dosing by at least 2 h. - Protein‑rich meals: may reduce levodopa bioavailability; advise timing.